<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547970" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547970/" /><meta name="ncbi_pagename" content="Bicalutamide - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Bicalutamide - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Bicalutamide" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/07/05" /><meta name="citation_pmid" content="31643303" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547970/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Bicalutamide" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/07/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547970/" /><meta name="description" content="Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury." /><meta name="og:title" content="Bicalutamide" /><meta name="og:type" content="book" /><meta name="og:description" content="Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547970/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Bicalutamide/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547970/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A3685046550B10000000008A202A4.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK547970_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK547970_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Bezlotoxumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Bictegravir/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547970_"><span class="title" itemprop="name">Bicalutamide</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 5, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Bicalutamide.OVERVIEW"><h2 id="_Bicalutamide_OVERVIEW_">OVERVIEW</h2><div id="Bicalutamide.Introduction"><h3>Introduction</h3><p>Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury.</p></div><div id="Bicalutamide.Background"><h3>Background</h3><p>Bicalutamide (bye" ka loo' ta mide) is an orally available nonsteroidal antiandrogen that is similar in structure to flutamide and nilutamide. Bicalutamide acts by binding to intracellular androgen receptors and competitively inhibiting the action of endogenous androgens on sensitive tissue, including testes, prostate, breast, skin and hypothalamus. Bicalutamide was approved for use in the United States in 1995. Current indications are for the therapy of prostate cancer in combination with luteinizing hormone releasing hormone (LHRH) analogs such as leuprolide or goserelin. Bicalutamide is available in tablets of 50 mg generically and under the trade name of Casodex. The recommended dose is 50 mg once daily. Common side effects of bicalutamide include fatigue, drowsiness, anxiety, gynecomastia and loss of libido.</p></div><div id="Bicalutamide.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Bicalutamide therapy is associated with mild, asymptomatic and transient elevations in serum aminotransferase levels in approximately 6% of patients. The frequency and height of the <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations appears to be less with bicalutamide than flutamide. Similarly, there have been rare case reports of clinically apparent liver injury due to bicalutamide, but less frequently than with flutamide. In the Spanish pharmacovigilance study, there were 11 reports of hepatotoxicity from bicalutamide, none of which were fatal. On the other hand, the product label for bicalutamide mentions that a few cases of fatal hepatic failure have been reported. The clinical pattern of liver injury with bicalutamide appears to resemble that of flutamide. The latency to onset is usually 2 to 3 months, but can be shorter with reexposure and occasionally arises 4 to 6 months after starting. The typical pattern of serum enzyme elevations is hepatocellular and severe, fulminant cases have been described. Rash, fever and eosinophilia are not common and autoantibody formation is not described.</p><p>Likelihood score: B (likely cause of clinically apparent liver injury).</p></div><div id="Bicalutamide.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of bicalutamide hepatotoxicity is unknown. It is metabolized by the liver via the cytochrome P450 system, largely via CYP 3A4 which it can inhibit and thus cause drug-drug interactions. Thus, liver injury from bicalutamide may be caused by toxic metabolites of the agent. The lower frequency of hepatotoxicity from bicalutamide compared to flutamide may be due to its lower dose or its lower rate of hepatic metabolism.</p></div><div id="Bicalutamide.Outcome_and_Management"><h3>Outcome and Management</h3><p>The mild <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations during bicalutamide therapy are usually self-limiting even with continuation of the medication. The rare instances of clinically apparent liver injury have ranged in severity from mild self-limiting cases to fatal acute liver failure. Monitoring of liver tests during therapy is recommended. There is no information on cross sensitivity to hepatic injury among the various antiandrogens. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.rechallenge/">Rechallenge</a> should be avoided and switching therapy to flutamide or nilutamide cannot be recommended.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/Anti-androgens/">Antiandrogens</a></p></div></div><div id="Bicalutamide.CASE_REPORTS"><h2 id="_Bicalutamide_CASE_REPORTS_">CASE REPORTS</h2><div id="Bicalutamide.Case_1._Acute_liver_failure"><h3>Case 1. Acute liver failure arising after two doses of bicalutamide.</h3><p>[Modified from: Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49: 283-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/9037299" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 60 year old man with prostate cancer developed acute liver failure following two doses of bicalutamide and a few days after stopping a 3 month course of flutamide. Liver test results were reported to be normal at the time of diagnosis of prostate cancer. Following an initial month of therapy with cyproterone acetate, flutamide and monthly subcutaneous goserelin acetate was started. Although flutamide was well tolerated, it was discontinued after 3 months and bicalutamide was substituted. After the second dose of bicalutamide, the patient developed jaundice and confusion. All medications were stopped and he was admitted for evaluation and therapy. He had no previous history of liver disease, no risk factors for viral hepatitis and no recent use of alcohol or acetaminophen. Serum bilirubin was 19.5 mg/dL, and serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> was markedly elevated with minimal increase in alkaline phosphatase levels (Table). The INR was 2.2. Tests for hepatitis A, B, C and for EBV infection were negative as were autoantibodies. An abdominal ultrasound revealed no evidence of biliary disease or liver metastasis. The patient developed mental obtundation and required intensive care support, vitamin K, and lactulose. After an initial period of worsening, he improved slowly. Eight weeks later, serum enzymes and bilirubin levels were normal.</p><div id="Bicalutamide.Key_Points"><h4>Key Points</h4><div id="Bicalutamide.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547970/table/Bicalutamide.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Bicalutamide.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Bicalutamide, 50 mg, 2 doses, and flutamide, 750 mg daily for 3 months</td></tr><tr><th id="hd_b_Bicalutamide.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Bicalutamide.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><th id="hd_b_Bicalutamide.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Bicalutamide.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">4+ (jaundice, hospitalization, coagulopathy and encephalopathy)</td></tr><tr><th id="hd_b_Bicalutamide.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Bicalutamide.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">2 days for bicalutamide, 3 months for flutamide</td></tr><tr><th id="hd_b_Bicalutamide.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Bicalutamide.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">2 months</td></tr><tr><th id="hd_b_Bicalutamide.T1_1_1_6_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Bicalutamide.T1_1_1_6_1" rowspan="1" colspan="1" style="vertical-align:top;">Flutamide, cyproterone acetate, goserelin acetate</td></tr></tbody></table></div></div></div><div id="Bicalutamide.Laboratory_Values"><h4>Laboratory Values</h4><div id="Bicalutamide.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547970/table/Bicalutamide.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Bicalutamide.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Bicalutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Bicalutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Bicalutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Bicalutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Bicalutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Bicalutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Bicalutamide.T2_1_1_1_1 hd_h_Bicalutamide.T2_1_1_1_2 hd_h_Bicalutamide.T2_1_1_1_3 hd_h_Bicalutamide.T2_1_1_1_4 hd_h_Bicalutamide.T2_1_1_1_5 hd_h_Bicalutamide.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Bicalutamide 50 mg daily for two days</td></tr><tr><td headers="hd_h_Bicalutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2</td><td headers="hd_h_Bicalutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Bicalutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2690</td><td headers="hd_h_Bicalutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">181</td><td headers="hd_h_Bicalutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">19.5</td><td headers="hd_h_Bicalutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">INR=2.2</td></tr><tr><td headers="hd_h_Bicalutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Bicalutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Bicalutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Bicalutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Bicalutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Bicalutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Asymptomatic</td></tr><tr><td headers="hd_h_Bicalutamide.T2_1_1_1_1 hd_h_Bicalutamide.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Bicalutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;35</b></td><td headers="hd_h_Bicalutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;130</b></td><td headers="hd_h_Bicalutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Bicalutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Bicalutamide.Comment"><h4>Comment</h4><p>Although widely cited as an example of bicalutamide hepatotoxicity, this case can only be said to be &#x0201c;possibly&#x0201d; related to bicalutamide and is much more likely due to flutamide hepatotoxicity with the typical abrupt hepatocellular pattern of injury arising after 3 months of therapy. Indeed, even with the most severe hepatic injury (in the absence of hemolysis), it would take more than 2 days for serum bilirubin to rise from normal to 19 mg/dL. Cyproterone has also be linked to similar cases of hepatocellular injury, but the appearance of jaundice several months after stopping this agent, makes it unlikely as the cause.</p></div></div></div><div id="Bicalutamide.PRODUCT_INFORMATION"><h2 id="_Bicalutamide_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Bicalutamide.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Bicalutamide &#x02013; Generic, Casodex&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=bicalutamide" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Bicalutamide.CHEMICAL_FORMULA_AND_STRUCT"><h2 id="_Bicalutamide_CHEMICAL_FORMULA_AND_STRUCT_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Bicalutamide.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547970/table/Bicalutamide.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Bicalutamide.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Bicalutamide.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Bicalutamide.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Bicalutamide.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Bicalutamide.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Bicalutamide.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Bicalutamide</td><td headers="hd_h_Bicalutamide.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135014383" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">90357-06-5</a></td><td headers="hd_h_Bicalutamide.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C18-H14-F4-N2-O4-S</td><td headers="hd_h_Bicalutamide.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK547970/bin/Bicalutamide_Structure.jpg" alt="Bicalutamide chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Bicalutamide.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Bicalutamide_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 05 July 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Bicalutamide.R1">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, p. 699.<div><i>(Expert review of hepatotoxicity published in 1999, mentions that flutamide has led to instances of severe hepatic necrosis and fulminant hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R2">DeLeve LD. Flutamide. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd Edition. Amsterdam: Elsevier, 2013. pp. 559.<div><i>(Textbook on drug induced liver injury mentions that flutamide has been implicated in 46 cases of severe liver injury with 20 fatalities; bicalutamide is not discussed).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R3">Moy B, Lee RJ, Smith M. Hormone therapy in prostate cancer. Natural products in cancer chemotherapy: hormones and related agents. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1763-9.<div><i>(Textbook of pharmacology and therapeutics; discusses the role of androgen receptor blockers in prostate cancer including bicalutamide, flutamide and nilutamide).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R4">Kennealey GT, Furr BJ. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am 1991; 18: 99-110.  [<a href="/pubmed/1992575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1992575</span></a>]<div><i>(Review of pharmacokinetics and early phase studies of bicalutamide for prostate cancer; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R5">Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patternson AL, Sarosdy M, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 1995; 45: 745-52.  [<a href="/pubmed/7538237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7538237</span></a>]<div><i>(Analysis of trial of bicalutamide vs flutamide in 813 men with prostate cancer at 60 sites; abnormal liver function reported in ~12% of flutamide vs ~8% of bicalutamide treated patients, but few details given as to nature, severity or reversibility).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R6">Kotake T, Usami M, Isaka S, Shimazaki J, Oishi K, Yoshida O, Ozono S, et al. [Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer] Hinyokika Kiyo 1996; 42: 143-53. Japanese.  [<a href="/pubmed/8712091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8712091</span></a>]<div><i>(Trial of escalating doses of bicalutamide for 12 weeks in 16 patients; 3 developed abnormal liver tests, but all reversed with stopping therapy [abstract only]).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R7">Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49: 283-4.  [<a href="/pubmed/9037299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9037299</span></a>]<div><i>(60 year old man with prostate cancer was given cytoproterone and flutamide for 3 months and then switched to bicalutamide developing jaundice after 2 doses [bilirubin 19.5 mg/dL, ALT 2690 U/L, Alk P 181 U/L, INR 2.2 and encephalopathy], improving within 2 months: Case 1).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R8">Chodak GW. Bicalutamide-associated fulminant hepatic failure. Urology 1997; 50: 1027.  [<a href="/pubmed/9426744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9426744</span></a>]<div><i>(Letter disputing the role of bicalutamide in case described by Dawson [1997] because flutamide had been stopped a few days before and was the more likely culprit).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R9">Schellhammer PF. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 50: 827.  [<a href="/pubmed/9372905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9372905</span></a>]<div><i>(Letter regarding case report by Dawson [1997] expressing doubt that the injury was due to bicalutamide [given for 2 days only] rather than flutamide [given for 3 months] or cyproterone [given for 1 month]).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R10">McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.  [<a href="/pubmed/10388026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10388026</span></a>]<div><i>(Overview of the safety and side effects of the nonsteroidal antiandrogens; ALT elevations in 6% receiving bicalutamide vs 10% with flutamide; clinically apparent hepatitis can occur but is rare).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R11">Palmberg C, Kylmala T, Tammela T. Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Br J Urol 1997; 79: 808-9.  [<a href="/pubmed/9158528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9158528</span></a>]<div><i>(46 year old man with prostate cancer developed ALT elevations [106 U/L] without jaundice after 21 months of flutamide [750 mg/day], which improved on stopping [to 73 U/L] and increased again [108 U/L] with restarting [500 mg/day]. Switching to bicalutamide [50 mg/day] was followed by decrease of ALT but not to normal [53 U/L]).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R12">Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56.  [<a href="/pubmed/9643663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9643663</span></a>]<div><i>(European trial of bicalutamide vs orchiectomy in 1453 men with prostate cancer, found bicalutamide monotherapy less effective; no mention of serious adverse events or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R13">Schellhammer PF, Davis JW. An evaluation of bicalutamide in the treatment of prostate cancer. Clin Prostate Cancer 2004; 2: 213-9.  [<a href="/pubmed/15072604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15072604</span></a>]<div><i>(Review of randomized trials of bicalutamide for prostate cancer with no new information on hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R14">Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004; 73: 289-95.  [<a href="/pubmed/15604569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15604569</span></a>]<div><i>(Systematic review of the literature from the Spanish pharmacovigilance group; 21 reports on hepatotoxicity of cyproterone, 46 flutamide, 4 nilutamide and only 1 bicalutamide; 6 cases of hepatocellular carcinoma linked to cyproterone therapy).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R15">Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006; 15: 253-9.  [<a href="/pubmed/16294367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16294367</span></a>]<div><i>(Analysis of spontaneous reporting to Spanish Pharmacovigilance system found 88 cases of flutamide, 11 bicalutamide and 15 cyproterone hepatotoxicity, latency 3-6 months; 2 fatalities, both from flutamide).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R16">Castro Beza I, S&#x000e1;nchez Ruiz J, Peracaula Espino FJ, Villanego Beltr&#x000e1;n MI. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol 2008; 10: 591-2.  [<a href="/pubmed/18796378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18796378</span></a>]<div><i> (61 year old man with prostate cancer developed jaundice 3 months after starting bicalutamide [bilirubin 11.5 mg/dL, ALT 1923 U/L, Alk P 169 U/L], and subsequently developed progressive liver failure and died).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R17">O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy 2008; 28: 1071-5.  [<a href="/pubmed/18657023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18657023</span></a>]<div><i>(59 year old man with prostate cancer developed abdominal pain 4 days after restarting bicalutamide [bilirubin not given, ALT 111 rising to 2050 U/L, INR 3.4], which was followed by multiorgan failure and death in 4 days).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R18">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to an antiandrogen).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R19">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to antiandrogen therapies). </i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R20">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 1 case [0.1%] was attributed to bicalutamide: 50 year old man with prostate cancer developed jaundice 4 months after starting bicalutamide [bilirubin 3.4 mg/dL, ALT 2412 U/L, Alk P 147 U/L, INR 1.2] with slow but complete resolution upon stopping).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R21">Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, et al. Atypical onset of bicalutamide-induced liver injury. World J Gastroenterol 2016; 22: 4062-5. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27099451" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>. [<a href="/pmc/articles/PMC4823258/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4823258</span></a>] [<a href="/pubmed/27099451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27099451</span></a>]<div><i> (62 year old man with prostate cancer developed jaundice 19 weeks after starting bicalutamide [biirubin 1.6 mg/dL, ALT 677 U/L, Alk P 87 U/L, INR 1.17], resolving completely within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Bicalutamide.R22">Hussain S, Haidar A, Bloom RE, Zayouna N, Piper MH, Jafri SM. Bicalutamide-induced hepatotoxicity: A rare adverse effect. Am J Case Rep 2014; 15: 266-70. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24967002" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>. [<a href="/pmc/articles/PMC4068966/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4068966</span></a>] [<a href="/pubmed/24967002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24967002</span></a>]<div><i>(81 year old man with prostate cancer developed jaundice 3 weeks after starting bicalutamide [bilirubin 3.7 mg/dL, ALT 576 U/L, Alk P 223 U/L, INR 1.5], which improved rapidly after stopping). </i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547970</span><span class="label">PMID: <a href="/pubmed/31643303" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643303</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Bezlotoxumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Bictegravir/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK547970&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK547970/?report=reader">PubReader</a></li><li><a href="/books/NBK547970/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK547970" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK547970" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Bicalutamide. [Updated 2017 Jul 5].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK547970/pdf/Bookshelf_NBK547970.pdf">PDF version of this page</a> (109K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=bicalutamide+AND+nitriles/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222006/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Bicalutamide: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=bicalutamide" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Bicalutamide: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4863904" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4863904" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4863904" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643810" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antiandrogens</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antiandrogens<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18635218" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.</a><span class="source">[J Urol. 2008]</span><div class="brieflinkpop offscreen_noflow">Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Urol. 2008 Sep; 180(3):921-7. Epub 2008 Jul 17.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9112515" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.</a><span class="source">[J Urol. 1997]</span><div class="brieflinkpop offscreen_noflow">Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Urol. 1997 May; 157(5):1731-5. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8560673" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.</a><span class="source">[Urology. 1996]</span><div class="brieflinkpop offscreen_noflow">The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furr BJ, Tucker H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Urology. 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17956709" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Combined androgen blockade in advanced prostate cancer: looking back to move forward.</a><span class="source">[Clin Genitourin Cancer. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Combined androgen blockade in advanced prostate cancer: looking back to move forward.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chodak G, Gomella L, Phung de H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Genitourin Cancer. 2007 Sep; 5(6):371-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643303" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643303" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604679909e31203af641c494">Bicalutamide - LiverTox</a><div class="ralinkpop offscreen_noflow">Bicalutamide - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:22:57-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A3685046550B10000000008A202A4&amp;ncbi_session=CE8A368504679901_2210SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547970%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK547970&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK547970/&amp;ncbi_pagename=Bicalutamide - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A368504679901_2210SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>